Daniel Skovronsky

Track

Insider profile

Currently holds a position at Eli Lilly and Co

Performance

Overall performance
3.9
Performance over holding periods
3.9
30 days 90 days 120 days
Average return 15% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
2 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories Eli Lilly and Co June 1, 2018 -
Daniel Skovronsky's trades of Eli Lilly and Co's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-12 2025-08-12
B Purchase
99,887 -48.6%
126.26
US$2,683,308 		99,887 -48.6% 126.26 US$2,683,308
2025-02-12 2025-02-10
PlS Planned sale
63,622 +20.4%
249.06
US$2,121,883 		63,622 +20.4% 249.06 US$2,121,883
2025-02-12 2025-02-10
PlS Planned sale
25,062 +39.5%
497.53
US$4,726,062 		25,062 +39.5% 497.53 US$4,726,062
2025-02-12 2025-02-10
PlS Planned sale
3,950 -3.2%
862.69
US$3,407,626 		3,950 -3.2% 862.69 US$3,407,626
2025-02-10 2025-02-10
PrS Proposed sale
5,000
863.19
US$4,315,954 		5,000 863.19 US$4,315,954
2019-10-28 2019-10-25
B Purchase
5,000 +7.1%
108.61
US$543,050 		5,000 +7.1% 108.61 US$543,050